TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36791161

Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-RSV preF protein vaccine
Number of subjects: 5782

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5782
Study: 36791160

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Number of subjects: 24966

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24966
Study: 36791166

Group type: EXPERIMENTAL
Intervention: Omission of radiotherapy
Number of subjects: 0
Study: 36791162

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (3-μg dose)
Number of subjects: 3013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3013
Study: 36791280

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 25237

Group type: COMPARATOR
Intervention: Epoetin beta
Number of subjects: 25237

Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 25237

Group type: COMPARATOR
Intervention: Methoxy polyethylene glycol-epoetin beta
Number of subjects: 25237

Group type: COMPARATOR
Intervention: Biosimilar epoetin
Number of subjects: 25237

Group type: COMPARATOR
Intervention: Biosimilar darbepoetin alfa
Number of subjects: 25237
Study: 36791586

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comfort-directed care
Number of subjects: 0
Study: 36791622

Group type: EXPERIMENTAL
Intervention: 4-phase rhinomanometry
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Elevated hypopnea apnea ratio
Number of subjects: 139
Study: 36791792

Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age-related dose adjustments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR) adjustments
Number of subjects: 0
Study: 36791845

Group type: EXPERIMENTAL
Intervention: Ampicillin + Roxithromycin
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cefuroxime + Roxithromycin
Number of subjects: 124
Study: 36791987

Group type: EXPERIMENTAL
Intervention: Podcast education (links to 7 labor-related podcast episodes)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control (usual education)
Number of subjects: 201
Study: 36791986

Group type: EXPERIMENTAL
Intervention: Bupivacaine (40 mL of 0.25% bupivacaine)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (40 mL of normal saline solution)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 36792107

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) Q4W
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) Q2W
Number of subjects: 932

Group type: COMPARATOR
Intervention: Placebo (from COAST-X)
Number of subjects: 932
Study: 36792266

Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiofrequency renal denervation
Number of subjects: 0
Study: 36792325

Group type: EXPERIMENTAL
Intervention: Standard care + Implantable Loop Recorder (ILR) + Holter monitor
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ILR-arm
Number of subjects: 200
Study: 36792323

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (>2 Gy/fraction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (1.8-2 Gy/fraction)
Number of subjects: 0
Study: 36792333

Group type: EXPERIMENTAL
Intervention: Weekly iron and folic acid (IFA) supplementation
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Daily multiple micronutrient supplements (MMSs)
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Weekly IFA and Daily MMSs
Number of subjects: 4500
Study: 36792337

Group type: EXPERIMENTAL
Intervention: tildrakizumab
Number of subjects: 500
Study: 36792338

Group type: EXPERIMENTAL
Intervention: Early breastfeeding initiation
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding to 6 months
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Birthweight regain by 2 weeks
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Growth outcomes at 6 months
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Preterm-SGA vs Preterm-AGA
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Term-SGA vs Preterm-AGA
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Not regaining birthweight by 2 weeks vs regaining
Number of subjects: 1114
Study: 36792367

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 0
Study: 36792378

Group type: EXPERIMENTAL
Intervention: Stroke participants
Number of subjects: 71

Group type: COMPARATOR
Intervention: Stroke-free controls
Number of subjects: 71
Study: 36792639

Group type: EXPERIMENTAL
Intervention: 0.5% isobaric bupivacaine (3 ml)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine (3 ml)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine (3 ml)
Number of subjects: 111
Study: 36792650

Group type: EXPERIMENTAL
Intervention: Short-term family-centered workshop (six 2-h sessions for six weeks)
Number of subjects: 101
Study: 36792782

Group type: EXPERIMENTAL
Intervention: LigaSure device
Number of subjects: 214

Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 214
Study: 36792805

Group type: EXPERIMENTAL
Intervention: Lisavanbulin administered as a 48-hour intravenous infusion at the recommended Phase 2 dose (RP2D) of 70 mg/m²
Number of subjects: 0
Study: 36792844

Group type: EXPERIMENTAL
Intervention: Acromegaly Symptom Diary (ASD)
Number of subjects: 60
Study: 36792998

Group type: EXPERIMENTAL
Intervention: T50 test
Number of subjects: 776
Study: 36793000

Group type: COMPARATOR
Intervention: ESPB (20 ml 0.25% bupivacaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ESPB + DEX (19 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 µg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ESPB + DEX
Number of subjects: 60
Study: 36793044

Group type: EXPERIMENTAL
Intervention: Run Daddy Run intervention
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 36793058

Group type: EXPERIMENTAL
Intervention: Nutri-Grade (NG) label on beverages
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control with Healthier Choice Symbol (HCS) logos
Number of subjects: 138
Study: 36793089

Group type: EXPERIMENTAL
Intervention: Women > 50 years
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Peri- and menopausal women
Number of subjects: 322

Group type: COMPARATOR
Intervention: Men
Number of subjects: 322

Group type: COMPARATOR
Intervention: All subjects
Number of subjects: 322
Study: 36793092

Group type: EXPERIMENTAL
Intervention: Niclosamide plus ramipril
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ramipril only (Control)
Number of subjects: 60
Study: 36793095

Group type: EXPERIMENTAL
Intervention: CAR-T therapy in Ph-like ALL
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CAR-T therapy in Ph+ ALL
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CAR-T therapy in other B-ALL
Number of subjects: 91
Study: 36793105

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Weight loss plus Mediterranean diet
Number of subjects: 192

Group type: COMPARATOR
Intervention: Typical diet controls
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Mediterranean diet, weight loss, weight loss plus Mediterranean diet
Number of subjects: 192
Study: 36793118

Group type: EXPERIMENTAL
Intervention: baricitinib 4 mg per day + hydroxychloroquine (HCQ) 400 mg per day
Number of subjects: 87

Group type: COMPARATOR
Intervention: hydroxychloroquine (HCQ) 400 mg per day alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: baricitinib + HCQ
Number of subjects: 87

Group type: COMPARATOR
Intervention: HCQ
Number of subjects: 87
Study: 36793385

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 36793451

Group type: EXPERIMENTAL
Intervention: CSF-targeted proteomics assessment of amyloid-beta peptides
Number of subjects: 719
Study: 36793546

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula (eHF-C)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey protein formula (eHF-W)
Number of subjects: 76
Study: 36793800

Group type: EXPERIMENTAL
Intervention: Unsupervised machine learning (k-means; km3d) modeling of clinical and functional disease measures
Number of subjects: 0
Study: 36794283

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 15 mg once daily, either as monotherapy after switching from MTX or in combination with stable background conventional synthetic DMARDs (csDMARDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 15 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36794354

Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel) at doses of 150, 300, or 450 × 10^6 CAR T cells
Number of subjects: 127
Study: 36794691

Group type: EXPERIMENTAL
Intervention: Intermuscular (IM) S-ICD implantation
Number of subjects: 290

Group type: COMPARATOR
Intervention: Subcutaneous (SC) S-ICD implantation
Number of subjects: 290
Study: 36794731

Group type: EXPERIMENTAL
Intervention: Targeted strategies implemented during Months 7-13 to improve recruitment.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recruitment strategies based on Consolidated Framework for Implementation Research.
Number of subjects: 60
Study: 36794816

Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides
Number of subjects: 0
Study: 36794963

Group type: EXPERIMENTAL
Intervention: Emerade® 500 μg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Emerade® 300 μg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epipen® 0.3 mg
Number of subjects: 12
Study: 36795232

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment at week 3
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment at week 12
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 148
Study: 36795303

Group type: EXPERIMENTAL
Intervention: Structured clinical pharmacist-delivered intervention (medication reconciliation and counselling at discharge, and two follow-up sessions at 4 and 8 weeks post-discharge)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Usual care (general usual care at discharge by clinical pharmacists)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Control group (discharged during weekends or after clinical pharmacists' working hours)
Number of subjects: 373
Study: 36795388

Group type: EXPERIMENTAL
Intervention: Atezolizumab with carboplatin plus nab-paclitaxel (IMpower130)
Number of subjects: 2503

Group type: EXPERIMENTAL
Intervention: Atezolizumab with carboplatin or cisplatin plus pemetrexed (IMpower132)
Number of subjects: 2503

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab plus carboplatin and paclitaxel (IMpower150)
Number of subjects: 2503

Group type: EXPERIMENTAL
Intervention: Atezolizumab-containing regimens
Number of subjects: 2503

Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 2503
Study: 36795465

Group type: EXPERIMENTAL
Intervention: JomPrEP smartphone app
Number of subjects: 50
Study: 36795510

Group type: EXPERIMENTAL
Intervention: Roll-over technique (ROG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard paracentesis (SPG)
Number of subjects: 62
Study: 36795619

Group type: EXPERIMENTAL
Intervention: ATA risk estimation
Number of subjects: 4773

Group type: EXPERIMENTAL
Intervention: Decision tree model
Number of subjects: 4773

Group type: EXPERIMENTAL
Intervention: Inclusion of additional variables
Number of subjects: 4773
Study: 36795707

Group type: EXPERIMENTAL
Intervention: Adolescent-mediated diabetes intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Leadership and life skills-focused control curriculum
Number of subjects: 160
Study: 36795739

Group type: EXPERIMENTAL
Intervention: Peer leadership program for Grade 6/7 students, delivered through a half-day workshop and 7 x 40 minute lessons, followed by a ten-week physical literacy program (2x30 minutes sessions per week).
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Peer leadership program for Grade 6/7 students.
Number of subjects: 359

Group type: COMPARATOR
Intervention: Waitlist control group (usual routines for Grade 3/4 students).
Number of subjects: 359
Study: 36795763

Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention; PrEP provided in electronic pillboxes; adherence measured as pillbox opened ≥80% of days.
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention; PrEP adherence during pregnancy follow-up.
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention; TFV-DP concentrations measured quarterly.
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention; pregnancy outcomes.
Number of subjects: 131
Study: 36795843

Group type: EXPERIMENTAL
Intervention: Darolutamide plus androgen-deprivation therapy and docetaxel
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Placebo plus androgen-deprivation therapy and docetaxel
Number of subjects: 1305
Study: 36795891

Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control medication
Number of subjects: 405
Study: 36796016

Group type: EXPERIMENTAL
Intervention: Oral azacitidine (CC-486) at 300 mg daily for 7 days before C1 of CHOP, and for 14 days before CHOP C2-6 plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral azacitidine (CC-486) plus CHOP
Number of subjects: 20
Study: 36796092

Group type: EXPERIMENTAL
Intervention: Transbronchial Lung Cryobiopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical Lung Biopsy
Number of subjects: 0
Study: 36796097

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36796234

Group type: EXPERIMENTAL
Intervention: xevinapant plus CRT
Number of subjects: 96

Group type: COMPARATOR
Intervention: placebo plus CRT
Number of subjects: 96
Study: 36796353

Group type: EXPERIMENTAL
Intervention: CCMDD program
Number of subjects: 390
Study: 36796440

Group type: EXPERIMENTAL
Intervention: Fecal short-chain fatty acids (SCFAs) and plasma cytokines (TNF-α)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fecal short-chain fatty acids (SCFAs) and plasma cytokines (IL-1RA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dietary markers (including animal protein)
Number of subjects: 34
Study: 36796484

Group type: EXPERIMENTAL
Intervention: STSP-0601 (0.01 U/kg, 0.04 U/kg, 0.08 U/kg, 0.16 U/kg, 0.32 U/kg, or 0.48 U/kg) in part A
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: STSP-0601 (0.16 U/kg, maximum of 6 4-hourly injections) in part B
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study: 36796498

Group type: EXPERIMENTAL
Intervention: Preoperative SABR (Stereotactic Ablative Body Radiotherapy) for early-stage breast cancer, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 36796573

Group type: EXPERIMENTAL
Intervention: vFFR guided coronary revascularization
Number of subjects: 2228

Group type: COMPARATOR
Intervention: FFR guided coronary revascularization
Number of subjects: 2228
Study: 36796574

Group type: EXPERIMENTAL
Intervention: Live-video-supervised exercise (aerobic+resistance) intervention
Number of subjects: 0
Study: 36796585

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon catheter
Number of subjects: 158
Study: 36796623

Group type: EXPERIMENTAL
Intervention: Race-Based Stress and Trauma Empowerment (RBSTE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 48
Study: 36796641

Group type: EXPERIMENTAL
Intervention: Booster antenatal corticosteroids (12 mg betamethasone every 24 hours for 2 days)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Booster antenatal corticosteroids
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 36796647

Group type: EXPERIMENTAL
Intervention: 3D optical imaging (3DO)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 133
Study: 36796762

Group type: EXPERIMENTAL
Intervention: Presence of mutations at positions 212 and 366 of EBV latent membrane protein 1 (LMP1)
Number of subjects: 872

Group type: COMPARATOR
Intervention: No mutations at positions 212 and 366 of EBV latent membrane protein 1 (LMP1)
Number of subjects: 872
Study: 36796859

Group type: EXPERIMENTAL
Intervention: Education and motor control exercises
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Education and strengthening exercises
Number of subjects: 123

Group type: COMPARATOR
Intervention: Education only
Number of subjects: 123
Study: 36796986

Group type: EXPERIMENTAL
Intervention: Structured semi-interactive stroke prevention package (SMS messages, videos, educational workbook)
Number of subjects: 4298

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4298

Group type: EXPERIMENTAL
Intervention: Structured semi-interactive stroke prevention package
Number of subjects: 4298
Study: 36797015

Group type: EXPERIMENTAL
Intervention: Active NMES group (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo NMES group (group B)
Number of subjects: 100
Study: 36797021

Group type: EXPERIMENTAL
Intervention: Mobile antenatal care clinic implementation
Number of subjects: 330

Group type: COMPARATOR
Intervention: Open-label control group
Number of subjects: 330
Study: 36797022

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoints stimulation (TEAS)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham TEAS (STEAS)
Number of subjects: 92
Study: 36797025

Group type: EXPERIMENTAL
Intervention: PreventT2 Together, the adapted couple-based curriculum
Number of subjects: 12

Group type: COMPARATOR
Intervention: CDC's PreventT2 curriculum designed for delivery to individuals
Number of subjects: 12
Study: 36797036

Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block (n=30) using 20 mL of adrenalized bupivacaine 0.50%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Periarticular local anesthetic infiltration (n=30) using 60 mL of adrenalized bupivacaine 0.25%
Number of subjects: 60
Study: 36797067

Group type: EXPERIMENTAL
Intervention: Preataxic participants
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ataxic patients
Number of subjects: 200

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 200
Study: 36797136

Group type: EXPERIMENTAL
Intervention: Low Carbohydrate (LC) diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High Carbohydrate/High Sugar (HCS) diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High Carbohydrate/Fiber (HCF) diet
Number of subjects: 20
Study: 36797201

Group type: EXPERIMENTAL
Intervention: 15.5 g carbohydrates
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 31 g carbohydrates
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study: 36797263

Group type: EXPERIMENTAL
Intervention: Governmental responses measured by the Containment and Health Index (CHI)
Number of subjects: 7645

Group type: EXPERIMENTAL
Intervention: Multigravida exposed to COVID-19 or living in countries with a higher number of deaths due to COVID-19
Number of subjects: 7645

Group type: EXPERIMENTAL
Intervention: Multigravida from countries with lower IHDI or CHI
Number of subjects: 7645

Group type: EXPERIMENTAL
Intervention: More restrictive measures
Number of subjects: 7645
Study: 36797356

Group type: EXPERIMENTAL
Intervention: BGB-A333 alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BGB-A333 plus tislelizumab
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BGB-A333 alone and in combination with tislelizumab
Number of subjects: 39
Study: 36797394

Group type: EXPERIMENTAL
Intervention: Protective lung ventilation (tidal volume set at 6 ml/Kg predicted body weight, PEEP 6 cmH2O)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 0
Study: 36797461

Group type: EXPERIMENTAL
Intervention: Specific mindfulness- and acceptance-based psychological intervention (MY-ENDO)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Carefully matched non-specific psychological intervention (Non-specific)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wait-list control group (WL)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Psychological interventions (MY-ENDO + Non-specific)
Number of subjects: 58
Study: 36797481

Group type: EXPERIMENTAL
Intervention: Tropifexor 10-90 μg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Tropifexor 140 μg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Tropifexor 200 μg
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 36797515

Group type: EXPERIMENTAL
Intervention: Implementation support programme including clinical training, supervision, appointing a family coordinator, toolkit, and fidelity measurements at baseline, 12, 18, and 24 months with on-site feedback and supervision.
Number of subjects: 14

Group type: COMPARATOR
Intervention: No implementation support (control group) with fidelity measurements at baseline and 24 months without feedback.
Number of subjects: 14
Study: 36797664

Group type: EXPERIMENTAL
Intervention: Ribociclib in combination with letrozole
Number of subjects: 2

Group type: COMPARATOR
Intervention: Palbociclib in combination with letrozole
Number of subjects: 2
Study: 36797680

Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACT)
Number of subjects: 50
Study: 36797744

Group type: EXPERIMENTAL
Intervention: Rivoceranib (apatinib) 300 mg once daily in combination with pembrolizumab 200 mg every 3 weeks
Number of subjects: 5
Study: 36797990

Group type: EXPERIMENTAL
Intervention: ETI therapy (elexacaftor/tezacaftor/ivacaftor)
Number of subjects: 20